Amendment 3 to Technology License Agreement Between NRC and Licensee – Stable Cells Annex

Contract Categories: Intellectual Property › License Agreements
Summary

This amendment updates the annex of a technology license agreement between the National Research Council (NRC) and the licensee. It specifies that the licensee will receive certain stable cell lines expressing various spike protein antigens through a service provider. Additional cell lines may be added with NRC's written approval and payment of applicable fees. The amendment clarifies the process for expanding the list of provided cell lines under the original agreement.

Read More Arrow
EX-10.7 4 ex10-7.htm

 

Exhibit 10.7

 

 

NRC INTERNAL USE: HHT -- PP&A

# A-0042398 (Orig. A-0039781)Page 1 of  2

 

 

Amendment 3 to

Technology License Agreement

  BUSINESS CONFIDENTIAL – PROTECTED B

 

AMENDED ANNEX A – Stable Cells

 

Stable Cells to be provided to Licensee through the Service Provider

 

1) CHO2353TM stable pool expressing the stabilized trimeric Wuhan spike protein antigen
2) CHO2353TM stable pool expressing the stabilized trimeric South African spike protein antigen
3) CHO2353TM stable pool expressing the stabilized trimeric DELTA Variant spike protein antigen
4) CHO2353TM stable pool expressing the stabilized trimeric OMICRON Variant spike protein antigen

 

For clarity, Additional Stable Cells could be added to the list upon obtaining the NRC’s prior written approval, satisfying all the NRC’s requirements in this respect and the payment of relevant fees as per stated in section 2.6.2 of the Original Agreement.

 

NRC INTERNAL USE: HHT -- PP&A

# A-0042398 (Orig. A-0039781)Page 2 of  2